Melanoma & Skin Cancer | Specialty

KEYNOTE-006: Results and Relevance

May 2nd 2015

Dr. Hamid on Using Biomarkers for Immunotherapy in Melanoma

May 1st 2015

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses the possibility of using biomarkers to select immunotherapy as a treatment option for patients with melanoma.

FDA Grants Priority Review to Frontline Nivolumab in Melanoma

April 30th 2015

The FDA has assigned a priority review designation to the PD-1 inhibitor nivolumab as a treatment for previously untreated patients with unresectable or metastatic melanoma.

FDA Panels Support Approval of T-VEC in Melanoma

April 29th 2015

In a combined decision, members of the FDA's Oncologic Drugs Advisory Committee and Cellular, Tissue and Gene Therapies Advisory Committee voted 22-1 to recommend approval of the oncolytic immunotherapy talimogene laherparepvec (T-VEC) as a treatment for patients with advanced melanoma.

Hodi Speaks to Significance of Phase II Data on Ipilimumab Plus Nivolumab in Melanoma

April 25th 2015

OncLive sat down with F. Stephen Hodi, director, Melanoma Center, director, Center for Immuno-Oncology, Dana-Farber Cancer Institute, to gain further insight into combination and sequencing strategies for patients with melanoma.

2015 AACR Annual Meeting Highlights

April 24th 2015

Adding Nivolumab to Frontline Ipilimumab Improves PFS by 60% in Melanoma

April 20th 2015

Frontline immunotherapy with nivolumab plus ipilimumab delayed disease progression by 60% compared with ipilimumab alone in patients with advanced melanoma.

Dr. Hodi on Nivolumab in Combination With Ipilimumab for Advanced Melanoma

April 20th 2015

F. Stephen Hodi, MD, discusses the results of a trial presented at the 2015 AACR Annual Meeting.

Frontline Pembrolizumab Trumps Ipilimumab in Head-to-Head Melanoma Trial

April 19th 2015

Pembrolizumab elicited significantly better outcomes compared with ipilimumab in a randomized phase III trial of patients with advanced melanoma.

Bispecific Immunotherapy Elicits Intriguing Responses in Melanoma

April 19th 2015

IMCgp100 yielded long-lasting responses in patients with advanced melanoma, according to results from a 17-patient expansion cohort presented at the 2015 AACR Annual Meeting.

Novel Doublet and Triplet Combo Studies Explode in Melanoma

April 16th 2015

In an interview with OncLive, Jeffrey S. Weber, MD, PhD, discussed combinations currently in development for patients with advanced metastatic melanoma, and key considerations in employing the new therapies in clinical practice.

Dr. LoRusso on Personalized Medicine for Melanoma

April 15th 2015

Patricia M. LoRusso, DO, Associate Director of Innovative Medicine, Yale Cancer Center, discusses the Dream Team Melanoma trial, which is investigating using personalized medicine to treat non-V600E melanoma subtypes.

Yale Launches National Study of Personalized Medicine for Metastatic Melanoma

April 15th 2015

Yale University has launched a multicenter clinical trial, sponsored by Stand Up to Cancer and Melanoma Research Alliance, that will apply the latest in personalized medicine technology to treat metastatic melanoma.

Dr. Sznol on Managing Toxicities in Treatment of Melanoma

April 15th 2015

Mario Sznol, MD, professor of medicine (medical oncology), clinical research program leader, Melanoma Program, Yale Cancer Center, discusses how to manage toxicities in treatment of melanoma.

New Rucaparib Designation, STRIVE Trial, 5-Year Ipilimumab Data, and More

April 12th 2015

Immunotherapy Innovator Jedd Wolchok Honored

April 11th 2015

Jedd D. Wolchok, MD, PhD, played an important role in the development of ipilimumab, the first drug to target an immune checkpoint as an anticancer strategy. He was honored in the Melanoma category with a 2014 Giants of Cancer Care® award.

Experts Explore Immunotherapy Frontier in Melanoma

April 10th 2015

Immunotherapy advances are among the emerging treatment approaches that make it an exciting time for patients with melanoma and their physicians.

Melanoma Excision Frequently Delayed in Medicare Population

April 8th 2015

One in five Medicare patients with melanoma waits more than 1.5 months after diagnosis to undergo surgery.

Abiraterone Label Expanded, Phase III Melanoma Data, SGR Repeal, and More

April 3rd 2015

Dr. Agarwala on the Role of Cytokines in the Immunotherapy Landscape

April 2nd 2015

Sanjiv S. Agarwala, MD, Chief of Medical Oncology, Hematology, St. Luke's Cancer Center and Temple University, discusses the differences between cytokines and other types of immunotherapies.